Bloomberg View columnist Barry Ritholtz looks at the people and ideas that shape markets, investing and business.
Follow Bloomberg reporters as they uncover some of the biggest financial crimes of the modern era. This documentary-style series follows investigative journalists as they uncover the truth
Tons of Aviation Jobs Up for Grabs as Singapore Races to Recruit
Robert Smith’s Vista Equity Snags Early $9 Billion for New Fund
EV Startup Electric Last Mile Warns It May Run Out of Cash in June
Amazon Shareholders Narrowly Approve Pay Plans for Executives
Relativity’s 3D Printed Rocket on Path for Summer Debut Flight
Trump Backs NRA in Gun Rights Pitch After Texas School Shootings
Texas Governor Abbott Says He’s ‘Livid’ About Inaccurate Police Account of Shooting
A $423 Billion Pension Giant Expands Its Growth-Equity Ambitions
Americans’ Savings Rate Drops to Lowest Since 2008 as Inflation Bites
Palm Beach Art Dealer Charged With Selling Fake Basquiat, Warhol
Stephen A. Smith Wants a Podcast — But Maybe Not at ESPN
Venice Has a 400-Year-Old Covid Monetary Lesson
A Crystal Clear Pool Will Cost a Lot More This Summer
Did US Consumer Spending Just Hit Its Peak?
Fewer Pilots Will Lead to a Summer of Flight Cancellations
It’s Going to Be a Great Summer for Car Rental Companies—But Not for You
Freedom to Travel This Summer Will Come at a Hefty Price
Apple Atlanta Workers Drop Bid for Union Vote Next Week, Claiming Intimidation
Wyoming’s Only Surgical Abortion Clinic Will Open Despite Arson
Lewis Hamilton Jewellery Exemption Extended to End of June
The World Isn’t Spending Enough to Prevent Disasters, UN Says
California, New Zealand Announce Climate Change Partnership
US Baby Formula Shortage Rate Jumps to 70% as Crisis Worsens
Inside the ‘Tight-Knit Community’ of Uvalde, Texas
How New York City Plans to Speed Up its Buses
Crypto Giant FTX Ready With Billions of Dollars for Acquisitions
Terra Stablecoin’s Woes Prompted in Part by Celsius Network Activities, Researcher Says
Bitcoin Breaks From Stocks and Keeps On Falling as Crypto Slides
Merck & Co.’s Covid-19 pill was cleared by U.S. regulators Thursday, giving high-risk patients a second at-home treatment just as the omicron variant is causing cases to surge around the country.
The drug, molnupiravir, received emergency authorization on the heels of Pfizer Inc.’s Covid pill being cleared Wednesday. The FDA said Merck’s drug is not recommended for use in pregnant people.